Our vision: Transformational outcomes. Uncompromising safety.

At Quell, we see a future where people living with refractory autoimmune disease can achieve safe, transformational and durable resolution of their disease from a single, outpatient dose of engineered nTregs.

Our Ambition

A different kind of cell therapy company

Simple. Scalable. Designed to serve many patients.

Cell therapy can deliver transformational outcomes, but first-generation therapies were built for life-threatening cancers treated in hospital and on platforms that are hard to scale. Autoimmune disease affects millions of people who need therapies that are effective, well tolerated and accessible outside hospital.

Quell is designing engineered nTreg therapies specifically for complex autoimmunity.

One product, many diseases

Developing pipeline-in-a-product candidates, designed to treat multiple complex autoimmune diseases.

Outpatient treatment model

Designing therapies to avoid lymphodepletion chemotherapy and toxicities such as cytokine release syndrome (CRS), local immune effector cell-associated toxicity syndrome (LICATS) so they could be given in the outpatient setting.

Built to scale

Manufacturing built to scale from the outset, with a clear roadmap to automation and lower costs.

People

A visionary team, passionately committed to delivering Quell's mission

Quell’s seasoned leadership team is dedicated to the delivery of transformative therapies to patients. Their extensive experience across all aspects of cell therapy development ensures continued leadership and innovation in the engineered Treg field.

Our Partners

Partnering is in our DNA

We recognize that winning in a pioneering field means collaborating with the smartest people, to gain the best insights. At Quell, we look to partner with the leaders in their field, who share the common goal of accelerating life changing therapies to patients.

Biopharma

In the spirit of ‘partnering with the best’, Quell is always looking for world-leading pharma partners to collaborate with, sharing a clear goal of bringing together complimentary skill sets and knowledge bases, which together help us move the field forward, develop better therapeutics and change patients lives.

Clinical & academic

Our CHILL study is led by world-leading rheumatology investigators across the UK, Germany and Spain, including the Kennedy Institute of Rheumatology, Friedrich-Alexander University Erlangen–Nuremberg, University of Leeds, University of Newcastle and Heinrich-Heine-University Düsseldorf. We also partner with scientific and clinical collaborators at King’s College London, UCL, UHN and Hannover Medical School.

Manufacturing & automation

Every patient with a refractory autoimmune condition should have the option of durable disease control. So, while we develop engineered nTreg therapies, we are also solving cell therapy’s scalability, cost and access challenges. We partner with the best manufacturing and automation partners in the field, who share our goals and values.

Investors

Our Partners

At Quell, we are passionate about our mission for bringing life-changing immune-therapies of the future, into our world of today – We are pleased to be partnered with investors who collectively share our passion and our values.

Quell Tx

Company